Intellia Therapeutics, Inc. (NTLA)
NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
Pre-market:
| Previous close | 21.17 |
| Open | 20.53 |
| Bid | 20.01 x 300 |
| Ask | 20.06 x 300 |
| Day's range | 19.64 - 20.66 |
| 52-week range | 19.64 - 47.48 |
| Volume | |
| Avg. volume | 1,549,385 |
| Market cap | 1.924B |
| Beta (5Y monthly) | 1.80 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -5.42 |
| Earnings date | 02 May 2024 - 06 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 70.96 |
ZacksIntellia (NTLA) to Report Q1 Earnings: What's in the Cards?
On Intellia's (NTLA) first-quarter 2024 earnings call, investors' focus is likely to be on the progress of its pipeline of genome-editing candidates.
ZacksEarnings Preview: Intellia Therapeutics, Inc. (NTLA) Q1 Earnings Expected to Decline
Intellia Therapeutics (NTLA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Simply Wall St.Intellia Therapeutics (NASDAQ:NTLA shareholders incur further losses as stock declines 9.9% this week, taking three-year losses to 65%
Investing in stocks inevitably means buying into some companies that perform poorly. But the long term shareholders of...
© 2024 Yahoo. All rights reserved.